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Summary A number of randomized studies have been carried out in the UK and USA to determine the optimal radiotherapy dose schedule
for advanced non-small-cell lung cancer (NSCLC). We have examined eight radiotherapy regimens from data taken from four randomized
phase III studies carried out in the UK (1264 patients): 10 Gy single fraction; 17 Gy in two fractions over 8 days; 30 Gy in ten fractions over 14
days; 22.5 Gy in five fractions in 5 days; 27 Gy in six fractions over 11 days; 30 Gy in six fractions over 11 days; 36 Gy in 12 fractions over 16
days; and 39 Gy in 13 fractions over 17 days. We compared the clinical results in palliation, toxicity and survival with four regimens taken from
one randomized study from the USA (365 patients): 40 Gy in 20 fractions over 4 weeks; 40 Gy 'split course' in ten fractions in 4 weeks; 50 Gy
in 25 fractions over 5 weeks; and 60 Gy in 30 fractions over 6 weeks. Using the linear-quadratic (LQ) radiobiological model, we have
calculated the radiobiological equivalent dose (BED) for acute-reacting tissues (BEDJ), late-reacting tissues (BED1 7) and tumour (BED2.),
and related the predicted response to the observed response in each tissue. There was a good correlation between the predicted response
and the reported response in the case of late-reacting tissue toxicty and tumour response. The model confirmed that, in good performance
status patients, a higher value for BED2, correlated with a higher degree of local control and survival and that radiotherapy regimens with a
higher value for BED1-7 were associated with five cases of cord myelopathy, if the spinal cord was not shielded. In poor performance status
patients the model suggested that the optimal regimen was a single fraction of 10 Gy because this resulted in an equivalent degree of
symptom control as other regimens, needed only one hospital visit and was less likely to result in cord damage, thus, allowing for the
possibility of retreatment at a later date.
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One consistency in the use ofradiotherapy for non-small-cell lung
cancer (NSCLC) is the continued variation in the radiation dose
and schedule. The great majority of patients with NSCLC are
incurable at the time ofdiagnosis. yet there is disagreement among
radiation oncologists as to whether such patients should receise
higher doses ofradiotherapy in an attempt to gain a greater degree
of local control. Higher doses ofradiotherapy may be given at the
cost of time and an increase in normal tissue toxicity. Moreover. it
is not clear whether improved thoracic control leads to any further
benefit in palliation or improvement in sur-ival in patients with
locally advanced or metastatic disease.
In this respect. there appears to be a divide in radiation treat-
ment strateaies between North America and the UK. In North
America. radiation doses are typically higher than in the UK and
are fractionated over 4-6 weeks. Perez et al (1980) carried out a
study in which 365 patients with locally advanced NSCLC were
randomized to receive:
1. a split course of20 Gs in five fractions. a 2-seek break.
20 Gy in five fractions:
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2. 40 Gv in 20 fractions. oser 4 weeks:
3. 50 Gs in 25 fractions over 5 w-eeks:
4. 60 Gv in 30 fractions over 6 w-eeks.
A significant degree of intrathoracic tumour control w-as seen
with increasing radiation dose and this correlated with a modest
improvement in sunis al (37-47 weeks). The split course
produced the worst results. Significant poor prognostic indicators
were found to be weight loss of > 10%. age > 70 years and low
Karnofskv score.
In contrast. the Medical Research Council Lung Cancer Working
Party (MRC LCWP) and the Bristol group sought to explore the rela-
tionship between radiation dose schedule and symptom control. thus
the primary end point has been a measurement of palliation rather
than sur isal. Four randomized studies hase been carried out:
1. 30 Gy in ten fractions over 2 wieeks ss. 17 Gy in tvio fractions
in 8 days. in patients with locally adsanced or metastatic
NSCLC (all performance statuses included) (MRC LCWP.
1991):
2. 17 Gy in two fractions over 8 days vs. a single 10 Gy. in poor
performance patients with locally advanced or metastatic
NSCLC (MRC LCWP. 1992):
3. 17 Gy in two fractions over 8 days ss. 22.5 Gy in fie frac-
tions oser 5 days. in locally adsvanced or metastatic disease (all
performance statuses included) (Rees et al 1997):
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4. 39 Gy in 13 fractions over 17 days (or 36 Gy in 12 fractions
over 16 days) vs. 17 Gy in two fractions. in good-performance
patients with locally advanced or metastatic NSCLC (MRC
LCWP, 1996).
In a fifth report on radiation myelopathy. using MRC Lung
Cancer Working Party data, an additional two regimens are
mentioned: 30 Gy in six fractions over 11 days and 27 Gy in six
fractions over 11 days (Macbeth et al. 1996). These schedules are
shown in Table 1. but full data on degree ofpalliation and survival
are not available in the published literature.
The conclusions from the first three studies indicated that 30 Gy
in ten fractions. 17 Gy in two fractions, 22.5 in five fractions or a
single fraction of 10 Gy were equivalent in terms of symptom
control. and there was no significant difference in overall survival.
However, the fourth study revealed that there was a modest
improvement in survival, in the good-performance group, for
those treated with the 39 Gy in 13 fraction arm (or 36 Gy in 12
fractions over 16 days) (9 months vs. 7 months), but at a cost of
normal tissue toxicity and inferior percentages forpalliation.
Because these patients were treated with radiation only, publica-
tions such as these enable us to use such data for dose-response
studies. Currently. many groups are using radiation in conjunction
with chemotherapy, orchemotherapy only, thus fuither pure radia-
tion studies appear unlikely. These studies provide an opportunity
to examine the relationship between radiation dose and response.
The purpose ofthis study was to compare the biological equivalent
dose (BED) to three main tissues: acute-reacting tissues, late-
reacting tissues and tumour. of each radiotherapy regimen (see
Tables 1 and 2). We aimed to determine which radiotherapy
regimen was likely to cause the least morbidity for the equivalent
or superior anti-tumour effect.
METHODS
Published data from the four UK NSCLC trials and the trial by
Perez et al (1980) were analysed (see Tables 1 and 2).
BED was calculated using the linear quadratic (LQ) model
(Barendsen, 1982: Fowler. 1989). The model was used in its
simplest form, i.e. the BED for each tissue was calculated using
equation (1) from knowledge ofthe number offractions (N). dose
per fraction (d) and tissue ac/ ratio:
BED = Nd [I +d(a)1 (1)
Altemative forns of the model allow for the effect of concurrent
repopulation in tumours or acute-responding tissues, but these
effects were not considered here as there is a paucity of data
relating to such events. Although there is fairly extensive data
relating to repopulation rates of squamous cell carcinoma of the
head and neck (Hendry et al, 1996), there is little reliable data
relating to repopulation of NSCLC or acute-responding tissues.
Furthermore, it is not clear how palliation response is influenced
(ifatall) by repopulation. Corrections forrepopulation would have
the effect of reducing the calculated BED values for acute and
tumourresponses, but the amount ofthe reduction is unlikely to be
significant for the shorter treatment regimens. i.e. as used in the
MRC studies.
The a/14 values reflect the fractionation sensitivity of specific
radiation responses and. for acute-reacting tissue. spinal cord and
tumour (NSCLC), were respectively assumed to be 10. 1.7 and
25 Gy. The choice of a4p = 10 Gy to characterize the acute
responses is selected with reference to datacompiledby Joinerand
van der Kogel (1997). and which show a moderately narrow
spread ofvalues (typically 7-13 Gy) for a range ofearly reactions.
The selection of a low a/15 value of around 1.7 Gy for the spinal
cord is important when considering potential long-term damage to
this structure. Joiner and van der Kogel (1997) have tabulated
experimentally determined values ofthis parameter and it is clear
that it is likely to be significantly lower than the generic value of3
Gy, which is often used forquantifying late reactions. This point is
amplified in the Results section. For the tumour response, an alp
value of25 Gy has been assumed. This implies a low sensitivity to
changes in fractionation. but the value selected is not especially
critical in the context of this paper. Assuming the more common
generic value of 10 Gy does not change any of the conclusions.
Similarly, the relative predictions based on BED calculations are
unchanged when tumour a/ is increased from 25 Gy to much
larger values. Throughout this article. each calculated BED value
is followed by a suffix which identifies the assumed a/13value.
The incidence ofdysphagia has been assumed to be an indicator
of acute-reacting tissue toxicity. and the incidence of spinal cord
toxicity has been assumed to be a measurement of late tissue
damage.
Accurate measurement of tumour response is problematic
because this is not directly measured in any study. Overall survival
may be considered as an indicator of likely intrathoracic tumour
response. but this has been disputed and some consider survival
dependent more on the presence ofdistant metastases. Therefore.
we have also considered the degree of palliation of cough.
haemoptysis and chest pain as an indicator oftumour response.
RESULTS
UK data
Spinalcord response
In Table 1. the eight radiotherapy regimens are listed in
descending order of magnitude of their spinal cord toxicity. as
judged by the rankings ofthe values ofBED17. Also shown in the
table is the number ofpatients in each group.
Ofthe seven regimens, the first five are associated with nominal
cord BEDs of 98 Gy or more. Five cases of myelopathy occurred
in the starred regimens. which happen also to involve the largest
number ofpatients. On the basis that a BED, 7 of - 100 Gy carries
some risk of late cord damage, three other regimens may fall into
this category: 6x 5 Gy, 12x 3 Gy and 6 x 4.5 Gy.The lack ofany
observed cases may be due to the smaller numbers of patients
involved in these three groups.
The bracketed numbers next to each value of BED1 7 are the
altemative ranking orders obtained ifana//p value of3 Gy is used
in place of 1.7 Gy. In the absence of specific values for a/pn a
generic value of 3 Gy is often used to characterize late-reacting
responses. It will be noted that the ranking changes are relatively
small, but that the largest (a drop from third to fifth rank) is seen
with 2 x 8.5 Gy. which is one of the regimens with which cord
myelopathy has been reported. This supports the premise that a
value of alp lower than 3 Gy should always be used in assessing
cord response because the enhanced sensitivity to small changes in
dose per fraction is then better predicted.
Acute tissue response
Acute toxicity appears to rise fairly quickly for aBED1O in excess
of30 Gy: reported dysphagia was significantly worse in the 39 Gy
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Table 1 Radiothery dose fractionation and bioogically equivalent dose (BED) in three tissues: acute-reacting tbssue (BED,), spinal cord (BED, 7) and
tumour (BED^,). The regimens are listed in order of decreasing spinal cord toxicity as determined fromx theBED,, values. The bracketed numbers in the BED,7
column show how the ranking order is changed if a genenc a/ of 3 Gy is used instead
Fracinaon No. of patient BED1, (Gy) BED17 (Gy) BED2 (Gy)
6 x 5 Gy in 11 days 36 45 118 (1) 36
13 x 3 Gy in 16 daysat 153 51 108 (2) 44
2 x 8.5 Gy in 6 daysa 635 31 102 (5) 23
12 x 3Gy in 15 days2 86 47 100 (3) 40
6 x 4.5 Gy in 7 days 47 39 98 (4) 32
10 x 3 Gy in 13 days 88 39 83 (6) 34
5 x 4.5 Gy in 4 days 105 33 82(7) 27
1 x 10 Gy in 0 days 114 20 69 (8) 14
aCord myelopathy reported; snificantty worse dysphagia reported.
Table 2 Radiotherapy dose fractionation and booxgical equivalent dose (BED) in three tissues: acute-reacting tissue (BED,). spinal cord (BED, ,) and tumour
(BED,,). Data taken from NSCLC study (Perez et al, 1980)
Fractkonati No. of pati BED,O(Gy) BED17(Gy) BED2 (Gy) Inciderce
intratsoracl
crrence (%)
30 x 2 Gy in 39 days 84 72 131 65 33
25 x 2 Gy in 32 days 91 60 109 54 39
20 x 2 Gy in 25 days 97 48 87 43 49
'Split course': 5 x 4 Gy, 2-week break, 93 56 134 46 44
5 x 4 Gy (overall: 25 days)
aln this study, lead shieding was used in the posteriorportais to shield the spinal cord. Therefore, the dose to the spinal cord is uncertain. Moreover, bte
incidene of cord myelopathy is not reported.
in 13 fractions (BEDo = 51 Gy) or 36 Gy in 12 fractions (BED10 =
47 Gy) compared with 17 Gy in two fractions (BED,0 = 31 Gy)
(MRC LCWP. 1996). In addition. a single fraction of 1OGy
(BED1O = 20 Gy) produced very little dysphagia compared with
17 Gy in two fractions (23% versus 56%) (MRC LCWP, 1992).
Macbeth et al (1996) have shown how the per cent of time for
which dysphagia was reported may be fitted with a radiobiological
model that combines radiation-induced stem cell depletion with
subsequent stem cell repopulation. Although dysphagia is tran-
sient its onset is most likely to be govemed by the initial net cell
depletion. of which a straightforward BED,0 value may provide a
reasonably adequate measure for the purpose of ranking likely
incidence ofdysphagia.
Tumour response
As discussed above. measurement of tumour response was indi-
rect. BEDD is highest for 39 Gy in 13 fractions and 36 Gy in 12
fractions. It is interesting to note that these regimens produced the
longest survival times. yet were inferior with regard to palliation of
symptoms. Therefore. no firm conclusions can be drawn with
regard to the radiobiological model predicting tumour response in
these studies. Although these BEDs are uncorrected for possible
repopulation, it is easy to show that. even if repopulation in
NSCLC occurred at the high rate observed in head and neck
tumours. the rankings of the two most potent regimens would not
be altered.
USA data (Perez et al, 1980)
The four regimens are listed in Table 2. It is clear from the model-
ling that 60 Gy in 30 fractions produces the highest likely tumour
response (BED,,) and highest acute-reacting tissue response
(BED10). The split course regimen produced the highest late tissue
response for a relatively low tumour response. However, in this
study. partial shielding of the spinal cord was used and accurate
data on the dose received at cord level is not available. Also of
note is that the predicted tumour response (BED,) corresponds
very well to the data for the incidence ofintrathoracic control and
overall survival (see Table 2). Twenty gray in ten continuous frac-
tions (BED,5 = 43.2 Gy) has the highest incidence of intrathoracic
recurrence (49%). and 60 Gy in 30 fractions (BED, = 64.8 Gy)
had the lowest (33%).
DISCUSSION
Radiobiological modelling may have a place as a complement to
clinical judgement. as. for example. in cases in which alternative
treatments for a particular site show unexpected differences in
radiation responses (Dale et al. 1997). The UK NSCLC studies and
the study by Perez et al (1980) provide useful data with which to
test the ability ofradiobiological models to predict ranking orders
of likely response. It is probable that further data on radiation
dose-response will no longer be available, as many groups are
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now using radiotherapy in conjunction with chemotherapy.
Because the UK studies are prospectively carried out primarily to
measure symptom control, data collection for acute and late tissue
toxicity was better than the measurement of tumour response. In
contrast, a more aggressive approach is adopted by Perez et al
(1980). in that relatively higher doses ofradiation are given. with
the primary aim of gaining intrathoracic control. Thus, data are
more complete on tumour response and less detailed on symptom
control or toxicity.
It is still unclear from this work and the literature as to whether
we can accurately predict the best regimen for tumour response,
and whether this will lead to the best symptom control and
survival. Using the UKdata, this exercise predicts that 39 Gy in 13
fractions is the most likely to produce the greatest tumour cell kill
(BED,5 = 44 Gy) although this also produced two incidences of
spinal cord myelopathy, which is in keeping with the model
prediction for late tissue damage (BED17 = 108 Gy). Thirty-nine
gray in 13 fractions produced a modest improvement in survival
compared with 17 Gy in two fractions (9 months vs. 7 months),
but no advantage in symptom control. The entry criteria of the
study by Perez et al (1980) stipulated that patients should have had
locally advanced but not metastatic NSCLC. Thus. these patients
were not strictly comparable to many of the patients in the UK
NSCLC studies, which allowed inclusion of patients with
metastatic disease. This may explain why median survival times
were overall greater in the Perez study compared with the MRC
studies. However, there is evidence of a dose-response effect in
that the highest radiobiological dose of 60 Gy in 30 fractions
produced the best intrathoracic tumour control and this corre-
sponded to longer survival times. Notably, the methods used to
define local control were not clearly stated and this is aproblem in
many studies of this nature. It is presumed that recurrence was
detected radiographically.
Taken together. the studies by Perez et al (1980) and the MRC
Lung Cancer Working Party (1996) indicate that, in the absence of
metastases, in good performance status (WHO grade 0-2), a radia-
tion dose, which translates to aBED,5 ofabove 40 Gy, produces a
benefit in local control and this appears to translate to a survival
advantage. However, consideration must be given to the fact that
the improvement in intrathoracic control and survival may be
modest and at the expense of increased normal tissue toxicity and
number ofhospital visits.
An audit of the radiation oncologists in the UK indicated that
there is a diversity in the radiation schedules used for treatment of
NSCLC (Maher et al, 1993). A reason for the variability may be
that radiation oncologists are aware ofapossible dose-response in
the good performance status patients and prefer to give their
patients the best possible chance ofincreased survival. Until more
accurate prognostic indicators are discovered, a number of clini-
cians may continue to use prolonged courses of radiotherapy to
treat many oftheir patients with advanced NSCLC.
The situation for the poor performance patients is clearer
median survival times are considerably lower (3-4 months) and
the aim should, therefore, be relief of symptoms with the least
toxicity. Data from the MRC studies indicate that a single fraction
of 10 Gy is associated with the lowest BEDs for all three bio-
logical end points considered. Therefore, in a clinical situation in
which a patient may be of low performance status (WHO grade
2-4), and with locally advanced or metastatic disease, a single
fraction of 10 Gy produces rapid relief of symptoms at the cost of
only one visit. In addition. the LQ model predicts that, of all the
regimens considered. it is least likely to lead to spinal cord
myelopathy and acute toxicity. There is now substantial experi-
mental evidence that long-term recovery does occur in the irradi-
ated cord and that retreatment (albeit with a reduced dose) is
feasible (Stewart. 1997). Should the patient survive longer than
expected, the 1 x 10 Gy regimen does allow some potential for
retreatment at a later date ifnew symptoms arise, although in indi-
vidual cases the true (rather than nominal) dose to the cord would
need to be taken into account.
The UK lung trials clearly indicate that the considerations
which apply when identifying effective palliative treatments in
radiotherapy are quite different from those which apply to radical
treatments. On the basis that palliative treatments are not usually
expected to involve near-tolerance irradiation ofnormal structures.
it might appear that there is little scope for biological modelling
predictions in this area. However, as this intercomparison shows,
even simple modelling goes some way to providing supporting
information regarding the likely expected ranking ofvarious regi-
mens. and prospective use of such modelling may help focus on
the issues involved and help with the early rejection of regimens
which are unlikely to achieve the clinically desired aim.
CONCLUSION
The linear quadratic model predicted the likely responses ofacute-
and late-normal effects associated with the treatment of NSCLC
with reasonable consistency. The same appears to be true of the
tumour responses, but this is a more problematic area as the role of
modelling in quantifying tumour palliation has yet to be fully iden-
tified We have used the model to compare various radiotherapy
regimens used in the UK and the USA. The model predicts that
in good performance status, non-metastatic NSCLC patients the
higherradiation dose schedules (39 Gy in 13 fractions, 50 Gy in 25
fractions, 60 Gy in 30 fractions) are associated with greater tumour
cell kill, which has been shown to translate to a modest improve-
ment in local control and survival but no improvement in palliation.
In particular, the 'split course' was predicted to have a poorer
tumour response and, because ofthe rather large dose per fraction
involved, has the highest likelihood ofspinal cord toxicity.
In the situation of poor performance status (WHO grade 2-4),
the linear quadratic model predicts that a single fraction of 10 Gy
is the optimum regimen forpalliation and leaves the possibility for
future radiotherapy ifnecessary.
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